Title:
PHARMACEUTICAL COMPOSITION, COMPLEMENTARY KIT AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/109880
Kind Code:
A1
Abstract:
A pharmaceutical composition, a complementary kit and an application thereof; the pharmaceutical composition comprises pramipexole and safinamide, the mass ratio of pramipexole to safinamide being 1:300-1:30; and the pharmaceutical composition can be used to prepare drugs for treating Parkinson's disease, has a good curative effect and has few side effects, and can more effectively improve the condition of a patient. The capabilities thereof in restoring dopamine levels are better than those from using pramipexole or safinamide alone. In addition, the composition has better neuroprotective activity, and therefore damage to the dopaminergic system and the normal sensitivity of the dopamine system to dopamine agonists are reduced. The described composition can restore or balance a potential unbalanced response to "increasing dopaminergic treatment" that is caused by the use of a dopamine agonist alone; insofar as the same or a better therapeutic effect is achieved, the composition can reduce the amount of pramipexole when used alone so as to reduce the risk of side effects and drug resistance.
More Like This:
Inventors:
SU WEI (CN)
XIA GUANGXIN (CN)
WANG XUESONG (CN)
KE YING (CN)
BI GUANGQING (CN)
HUANG JIAN (CN)
XIA GUANGXIN (CN)
WANG XUESONG (CN)
KE YING (CN)
BI GUANGQING (CN)
HUANG JIAN (CN)
Application Number:
PCT/CN2020/130345
Publication Date:
June 10, 2021
Filing Date:
November 20, 2020
Export Citation:
Assignee:
SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN)
International Classes:
A61K31/428; A61K31/165; A61P25/16
Domestic Patent References:
| WO2017072335A1 | 2017-05-04 | |||
| WO2019036624A1 | 2019-02-21 | |||
| WO2009147681A1 | 2009-12-10 |
Foreign References:
| CN102105169A | 2011-06-22 | |||
| CN104168896A | 2014-11-26 | |||
| CN109803663A | 2019-05-24 | |||
| CN201911239173A | 2019-12-06 |
Other References:
ZHANG, NA: "Progress of Monoamine Oxidase Inhibitors for Neurodegenerative Diseases", THE JOURNAL OF MEDICAL THEORY AND PRACTICE, vol. 28, no. 13, 31 July 2015 (2015-07-31), pages 1713 - 1715,1718, XP055818688
STOCCHI FBORGOHAIN RONOFRJ MSCHAPIRA AHBHATT MLUCINI V ET AL.: "A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients", MOV DISORD OFF J MOV DISORD SOC., vol. 27, no. 1, 2012, pages 106 - 12
See also references of EP 4070793A4
STOCCHI FBORGOHAIN RONOFRJ MSCHAPIRA AHBHATT MLUCINI V ET AL.: "A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients", MOV DISORD OFF J MOV DISORD SOC., vol. 27, no. 1, 2012, pages 106 - 12
See also references of EP 4070793A4
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: